Zobrazeno 1 - 10
of 159
pro vyhledávání: ''
Autor:
RL Moroose, Cheryl Aylesworth, K. Tkaczuk, Christine E. Simmons, Melody A. Cobleigh, Michaela Tsai, Erika Hamilton, Eva Harder Brix, Hugues Bourgeois, David Cameron, Hatem Soliman, Wentao Feng, Jorge Ramos, Michelina Cairo, Sherene Loi, Martin Andersson, Anthony Gonçalves, Mafalda Oliveira, Lisa A. Carey, Belinda Yeo, Paula R. Pohlmann, Alicia Okines, Mattea Reinisch
Publikováno v:
Cancer Research. 81:PD3-08
Background Tucatinib (TUC) is a highly selective oral tyrosine kinase inhibitor of HER2 with minimal inhibition of EGFR. It was recently approved by the FDA for patients (pts) with HER2+ metastatic breast cancer (MBC), including pts with brain metast
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Autor:
Yu-Ming Shen, Dejan Juric, Murat Akdere, Aleix Prat, Hope S. Rugo, Stephen Chia, Christina Arce, Florence Lerebours, Nicholas C. Turner, Eva Ciruelos, Pamela Drullinsky, Rafael Villanueva Vazquez
Publikováno v:
Cancer Research. 81:PD2-07
Introduction: Mutations in PIK3CA, which encodes the α-isoform of phosphatidylinositol 3-kinase (PI3Kα), occur in ~40% of patients (pts) with HR+, HER2- ABC and can contribute to endocrine resistance. Alpelisib (ALP), a PI3Kα-selective inhibitor a
Autor:
Kathleen Dorris, Olivia Campagne, Arzu Onar-Thomas, Tina Young Poussaint, Clinton F. Stewart, Lindsey Hoffman, Eugene Hwang, Haitao Pan, Patricia Baxter, Ira J. Dunkel, Maryam Fouladi, Mariko DeWire, Andrew Bukowinski, Christine Fuller, Tong Lin, Matthias A. Karajannis, Angela Waanders
Publikováno v:
Clin Cancer Res
Purpose: Genomic aberrations in cell cycle and PI3K pathways are commonly observed in pediatric brain tumors. This study determined the MTD/recommended phase II dose (RP2D) of ribociclib and everolimus and characterized single-agent ribociclib concen
Autor:
Carine Bellera, Jean-Philippe Metges, Carlos Gomez-Roca, Simon Pernot, François Le Loarer, Celine Auzanneau, Jean-Philippe Guegan, Isabelle Soubeyran, Sophie Cousin, Alban Bessede, Antoine Adenis, Antoine Italiano, Coralie Cantarel, Michèle Kind
Publikováno v:
Clinical Cancer Research. 27:2139-2147
Purpose: Regorafenib is synergistic with immune checkpoint inhibition in colorectal cancer preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial. Regorafenib was given 3 weeks on/1 week off, 160 mg every day; av
Autor:
Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid
Publikováno v:
Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab pl
Autor:
Françoise Rimareix, Olivier Mir, Leila Haddag-Miliani, Etienne Rouleau, Charles Honoré, Olaf Mercier, Carine Ngo, Anaïs Brunet, Andrea Cavalcanti, Charles Court, Sarah Dumont, Sylvain Briand, Axel Le Cesne, Cécile Le Péchoux, Julien Domont, Antonin Levy, Elie Fadel, Julien Adam, Ali N. Chamseddine, Matthieu Faron, Arnaud Bayle
Publikováno v:
Clinical Cancer Research. 26:6277-6283
Purpose: Desmoid-type fibromatosis (DF) are locally aggressive neoplasms, with a need for effective systemic treatment in case of progression to avoid the short- and long-term complications of local treatments. Experimental Design: We retrospectively
Autor:
Zhengjia Chen, Fadlo R. Khuri, Sreenivas Nannapaneni, Dong M. Shin, Qiuying Shi, Conor E. Steuer, Jonathan J. Beitler, Mark W. El-Deiry, Adam M. Klein, Mihir R. Patel, Taofeek K. Owonikoko, Yuan Liu, Amy Y. Chen, Steven M. Roser, Zhuo Georgia Chen, Suresh S. Ramalingam, Nabil F. Saba
Publikováno v:
Clinical Cancer Research. 26:5860-5868
Purpose: On the basis of synergistic effects between green tea polyphenon E (PPE) and EGFR–tyrosine kinase inhibitor in preclinical studies, we conducted a phase Ib study of the PPE and erlotinib combination in patients with advanced premalignant l
Autor:
Z Yang, Arlene Chan, Pierfranco Conte, Sara M. Tolaney, Thomas Bachelot, Yanyun Chen, Nan Lin, Véronique Diéras, Peter Kabos, Ahmad Awada, Carey K. Anders, Melissa M. Bear, Solmaz Sahebjam, Denise A. Yardley, Emilie Le Rhun, Sonya C. Chapman
Publikováno v:
Clinical Cancer Research. 26:5310-5319
Purpose:The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor–positive (HR+) metastatic breast cancer (MBC). Se
Autor:
John J. Garber, James M. Richter, David A. Drew, Manish Gala, Marina V. Magicheva-Gupta, Madeline M. Schuck, Dylan C. Zerjav, Patrick Miller, Joseph C. Yarze, Francis Colizzo, Hamed Khalili, Kyle Staller, Peter J. Carolan, Ginger L. Milne, Andrew T. Chan, Oliver Takacsi-Nagy, Norman S. Nishioka, Katheleen O. Stewart, Giovanna Petrucci, Wenjie Ma, Carlo Patrono, Samantha M. Chin, Amit Joshi, Lawrence R. Zukerberg, Dana Meixell, Daniel C. Chung, Jennifer Mackinnon Krems, Katherine K. Gilpin, Melanie P. Parziale, Emily N. Pond, Molin Wang, Bianca Rocca
Publikováno v:
Cancer Prev Res (Phila)
Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those mos